By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
Palestine weekly wrap: Protests sweep West Bank after death penalty law - 2Germany paves the way for tighter EU asylum rules
- 3The Beginning Of The End For Fossil Fuels Can Start In Colombia
- 4Avoid This Common Mistake When Planning Sightseeing Activities For Your Trip To Italy
- 5Limited Rain Chances in Brazil Boost Coffee Prices
- What's inside Mexico's Popocatépetl? Scientists obtain first 3D images of the whole volcano
- Explainer-What has happened to the damaged spacecraft at China's space station?
- Which Countries Would Suffer Most in a Global Energy Shutdown? This Study Has Answers
- 7 Fun Plans to Make Film Evenings Seriously Invigorating (You'll Cherish #5!)
- The moon and sun figure big in the new year's lineup of cosmic wonders
- Figure out How to Store Your Gold Ventures: A Thorough Aide safely
- The most effective method to Shake Hands Expertly: A Bit by bit Guide
- 4 buzzy new TV shows to watch — plus the return of 'The Comeback,' 'Jury Duty' and more
- 3 Italian City Cars That Outsmarted Regulations and Rivals
